[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration].
The effect of a new potential antiparkinsonian drug, N-(2-adamantyl)hexamethyleneimine hydrochloride (A-7), upon some behavioral parameters was studied in rats after subchronic 14-day treatment. Also studied was the effect of abrupt termination of a prolonged (22-day) drug administration. The subchronic treatment with A-7 at a dose of 10, 20, or 40 mg/kg did not produce significant changes in coordination, explorative behavior, muscle tone, and aggression level. At the same time, the 14-day treatment with A-7 at a dose of 10 mg/kg increased the pain threshold; A-7 at a dose of 40 mg/kg (but not 10 or 20 mg/kg) increased the spontaneous motor activity. Upon abrupt termination of the drug administration after a prolonged treatment sensitivity of the test animals with respect to the MFTP neurotoxin as compared to that observed in the non-drug control group.
Val'dman
E A
EA
Laboratory of Psychopharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
D000218:Adamantane / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000374:Aggression / Q000187:drug effects; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005106:Exploratory Behavior / Q000187:drug effects; D007097:Imines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009129:Muscle Tonus / Q000187:drug effects; D017288:Pain Threshold; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D000978:Antiparkinson Agents; D007097:Imines; C122112:N-(2-adamantyl)hexamethylenimine; D000218:Adamantane